3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704)

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2015-09, Vol.51, p.S674-S674
Main Authors: Kaufman, H.L, Andtbacka, R.H.I, Collichio, F.A, Wolf, M, Li, A, Shilkrut, M, Murugappan, S, Zhao, Z, Puzanov, I, Ross, M
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)31848-2